- Home
- BIPC vs TNGX Comparison
BIPC vs TNGX Comparison
Compare BIPC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIPC | TNGX |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BIPC | TNGX |
|---|---|---|
| Price | $40.27 | $25.15 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $45.00 | $21.78 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $5.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $34.18 | $6.25 |
| 52 Week High | $51.72 | $34.39 |
Technical Indicators
Market Signals| Indicator | BIPC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 40.16 |
| Support Level | $40.03 | $19.74 |
| Resistance Level | $42.84 | $25.76 |
| Average True Range (ATR) | 1.41 | 1.58 |
| MACD | -0.12 | -0.28 |
| Stochastic Oscillator | 29.52 | 7.31 |
Price Performance
Historical ComparisonAbout BIPC Brookfield Infrastructure Corporation
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom, United States, France, Switzerland, Singapore, China, Denmark, Hong Kong, Germany and Others.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.